Persistent Asset Partners Ltd Raises Position in ANI Pharmaceuticals, Inc. $ANIP

Persistent Asset Partners Ltd raised its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 98.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,320 shares of the specialty pharmaceutical company’s stock after acquiring an additional 7,112 shares during the quarter. Persistent Asset Partners Ltd owned approximately 0.06% of ANI Pharmaceuticals worth $1,130,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of ANIP. Arrowstreet Capital Limited Partnership bought a new stake in shares of ANI Pharmaceuticals during the 3rd quarter valued at $32,992,000. Balyasny Asset Management L.P. raised its position in shares of ANI Pharmaceuticals by 2,785.7% during the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock valued at $26,211,000 after purchasing an additional 276,233 shares during the period. Divisadero Street Capital Management LP bought a new stake in shares of ANI Pharmaceuticals during the 3rd quarter valued at $21,454,000. Rubric Capital Management LP raised its position in shares of ANI Pharmaceuticals by 354.7% during the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock valued at $16,813,000 after purchasing an additional 200,998 shares during the period. Finally, UBS Group AG raised its position in shares of ANI Pharmaceuticals by 45.8% during the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after purchasing an additional 185,172 shares during the period. 76.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other ANI Pharmaceuticals news, Director Patrick D. Walsh sold 10,000 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $80.63, for a total value of $806,300.00. Following the sale, the director directly owned 38,432 shares in the company, valued at approximately $3,098,772.16. The trade was a 20.65% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Thomas Andrew Rowland sold 459 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $79.21, for a total transaction of $36,357.39. Following the completion of the sale, the senior vice president owned 38,271 shares in the company, valued at approximately $3,031,445.91. This represents a 1.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 79,016 shares of company stock worth $6,195,991 in the last 90 days. 8.10% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on ANIP. Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Zacks Research downgraded shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, June 1st. Five investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $107.33.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP opened at $83.00 on Wednesday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The company has a market cap of $1.89 billion, a P/E ratio of 21.01 and a beta of 0.44. The firm’s fifty day moving average is $80.06 and its two-hundred day moving average is $79.40. ANI Pharmaceuticals, Inc. has a 52-week low of $62.60 and a 52-week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.77. The company had revenue of $237.46 million for the quarter, compared to the consensus estimate of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. ANI Pharmaceuticals’s revenue for the quarter was up 20.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, analysts anticipate that ANI Pharmaceuticals, Inc. will post 8.07 EPS for the current fiscal year.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.